logo
  

ZeroFox Holdings Q4 Net Loss Widens, Despite Higher Revenues

ZeroFox Holdings, Inc. (ZFOX), an enterprise software-as-a-service company in external cybersecurity, reported Friday that its fourth-quarter net loss after tax was $234.80 million, sharply wider than last year's loss of $16.49 million.

Loss per share was $1.85, compared to loss of $0.14 per share a year ago.

The company, which is in deal to be acquired by private equity firm Haveli Investments, reported that total revenues climbed 33 percent to $60.51 million from $45.40 million a year earlier.

Annual Recurring Revenue was $188.4 million, an increase of 20 percent year-over-year.

As announced on February 6, ZeroFox will be bought by Haveli Investments in an all-cash transaction with an enterprise value of approximately $350 million.

The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including approval by ZeroFox stockholders and the receipt of required regulatory approvals.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AbbVie (ABBV) Monday announced a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage neuroscience biotech firm, to develop next-generation treatment approaches and unmet needs in psychiatric disorders. AbbVie noted that the first-generation compounds may... Healthwest Minerals, Inc. d/b/a Mt. Capra Products has recalled 1,506 boxes of Goat Milk Formula Recipe Kit, also urging consumers to immediately discontinue use of the product as infant formula. The firm does not recommend using this product for infants from 0-12 months of age. Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
RELATED NEWS
Follow RTT